Rui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rui Zhang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Aimin Wang
Beijing Laboratory of Biomedical Imaging, Beijing Municipal Education Commission, Beijing, China
2 shared publications - Bosong Yu
School of Instrumentation and Optoelectronic Engineering, Beihang University, Beijing 100191, China
2 shared publications - Dawei Li
College of Future Technology, Peking University, Beijing 100871, China
2 shared publications - Lishuang Feng
School of Instrumentation and Optoelectronic Engineering, Beihang University, Beijing 100191, China
2 shared publications - Qing-Di Cheng
Zhongshan Institute for Drug Discovery, Chinese Academy of Sciences, Zhongshan 528400, China
2 shared publications - Xiao Jia
Organic Chemistry Department of Chemistry Faculty of Mathematics Informatics and Natural Sciences Universität Hamburg Hamburg Germany
2 shared publications
Latest Publications
- Open Access
- 4 June 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (6) , 357
Nonlinear Imaging Detection of Organ Fibrosis in Minute Samples for Early Stage Utilizing Dual-Channel Two-Photon and Second-Harmonic Excitation
Histopathological staining remains the fibrosis diagnostic gold standard yet suffers from staining artifacts and variability. Nonlinear optical techniques (e.g., spontaneous fluorescence, Second Harmonic Generation) enhance accuracy but struggle with rapid trace-level detection of fibrosis. To address these limitations, a dual-channel nonlinear optical imaging system with excitation wavelengths at 780 nm and 820 nm was developed, enabling simultaneous spontaneous fluorescence and second-harmonic generation imaging through grid localization. This study applies dual-modality nonlinear imaging to achieve label-free, high-resolution visualization of pulmonary and renal fibrosis at the ECM microstructure scale. Through leveraging this system, it is demonstrated that collagen can be rapidly detected via spontaneous fluorescence at 780 nm, whereas the spatial distribution of collagen fibrils is precisely mapped using Second Harmonic Generation at 820 nm. This approach allows for the rapid and sensitive detection of trace fibrosis in a 5-day unilateral ureteral obstruction mouse model. Additionally, we identify that the elastic fibers, which can also be visualized, provide a foundation for staging diagnosis and delivering accurate and quantitative data for pathological studies and analysis. The research findings underscore the potential of this dual-channel nonlinear optical imaging system as a powerful tool for rapid, precise, and noninvasive fibrosis detection and staging.
- 4 June 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (6) , 357
Open AccessNonlinear Imaging Detection of Organ Fibrosis in Minute Samples for Early Stage Utilizing Dual-Channel Two-Photon and Second-Harmonic Excitation
Histopathological staining remains the fibrosis diagnostic gold standard yet suffers from staining artifacts and variability. Nonlinear optical techniques (e.g., spontaneous fluorescence, Second Harmonic Generation) enhance accuracy but struggle with rapid trace-level detection of fibrosis. To address these limitations, a dual-channel nonlinear optical imaging system with excitation wavelengths at 780 nm and 820 nm was developed, enabling simultaneous spontaneous fluorescence and second-harmonic generation imaging through grid localization. This study applies dual-modality nonlinear imaging to achieve label-free, high-resolution visualization of pulmonary and renal fibrosis at the ECM microstructure scale. Through leveraging this system, it is demonstrated that collagen can be rapidly detected via spontaneous fluorescence at 780 nm, whereas the spatial distribution of collagen fibrils is precisely mapped using Second Harmonic Generation at 820 nm. This approach allows for the rapid and sensitive detection of trace fibrosis in a 5-day unilateral ureteral obstruction mouse model. Additionally, we identify that the elastic fibers, which can also be visualized, provide a foundation for staging diagnosis and delivering accurate and quantitative data for pathological studies and analysis. The research findings underscore the potential of this dual-channel nonlinear optical imaging system as a powerful tool for rapid, precise, and noninvasive fibrosis detection and staging.
- Open Access
- 30 April 2025
- Published by MDPI AG in Preprints.org
Nonlinear Imaging Detection of Organ Fibrosis in Minute Samples for Early Stage Utilizing Dual-Channel Two-Photon Excitation
Histopathological staining remains the fibrosis diagnostic gold standard yet suffers from staining artifacts and variability. Although nonlinear optical techniques (e.g., spontaneous fluorescence, Second Harmonic Generation) enhance accuracy but struggle with rapid trace-level detection of fibrosis. To address these limitations, a dual-channel nonlinear optical imaging system with excitation wavelengths at 780 nm and 820 nm was developed, enabling simultaneous spontaneous fluorescence and second-harmonic generation imaging through grid localization. This study applies dual-modality nonlinear imaging to achieve label-free, high-resolution visualization of pulmonary and renal fibrosis at the ECM microstructure scale. Through leveraging this system, it is demonstrated that collagen can be rapidly detected via spontaneous fluorescence at 780 nm, whereas the spatial distribution of collagen fibrils is precisely mapped using Second Harmonic Generation at 820 nm. This approach allows for the rapid and sensitive detection of trace fibrosis in a 5-day unilateral ureteral obstruction mouse model. Additionally, we identify that elastic fibers, which can also be visualized, provide a foundation for staging diagnosis and delivering accurate and quantitative data for pathological studies and analysis. The research findings underscore the potential of this dual-channel nonlinear optical imaging system as a powerful tool for rapid, precise, and non-invasive fibrosis detection and staging.
- 30 April 2025
- Published by MDPI AG in Preprints.org
Open AccessNonlinear Imaging Detection of Organ Fibrosis in Minute Samples for Early Stage Utilizing Dual-Channel Two-Photon Excitation
Histopathological staining remains the fibrosis diagnostic gold standard yet suffers from staining artifacts and variability. Although nonlinear optical techniques (e.g., spontaneous fluorescence, Second Harmonic Generation) enhance accuracy but struggle with rapid trace-level detection of fibrosis. To address these limitations, a dual-channel nonlinear optical imaging system with excitation wavelengths at 780 nm and 820 nm was developed, enabling simultaneous spontaneous fluorescence and second-harmonic generation imaging through grid localization. This study applies dual-modality nonlinear imaging to achieve label-free, high-resolution visualization of pulmonary and renal fibrosis at the ECM microstructure scale. Through leveraging this system, it is demonstrated that collagen can be rapidly detected via spontaneous fluorescence at 780 nm, whereas the spatial distribution of collagen fibrils is precisely mapped using Second Harmonic Generation at 820 nm. This approach allows for the rapid and sensitive detection of trace fibrosis in a 5-day unilateral ureteral obstruction mouse model. Additionally, we identify that elastic fibers, which can also be visualized, provide a foundation for staging diagnosis and delivering accurate and quantitative data for pathological studies and analysis. The research findings underscore the potential of this dual-channel nonlinear optical imaging system as a powerful tool for rapid, precise, and non-invasive fibrosis detection and staging.
- Open Access
- 10 January 2022
- Published by MDPI AG in Kidney and Dialysis
- Vol. 2 (1) , 16-37
Antisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease
Chronic kidney disease (CKD) is a global public health issue that places an increasing burden on the healthcare systems of both the developed and developing countries. CKD is a progressive and irreversible condition, affecting approximately 10% of the population worldwide. Patients that have progressed to end-stage renal disease (ESRD) require expensive renal replacement therapy, i.e., dialysis or kidney transplantation. Current CKD therapy largely relies on the use of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs). However, these treatments by no means halt the progression of CKD to ESRD. Therefore, the development of new therapies is urgently needed. Antisense oligonucleotide (ASO) has recently attracted considerable interest as a drug development platform. Thus far, eight ASO-based drugs have been granted approval by the US Food and Drug Administration for the treatment of various diseases. Herein, we review the ASOs developed for the identification of CKD-relevant genes and/or the simultaneous development of the ASOs as potential therapeutics towards treating CKD.
- 10 January 2022
- Published by MDPI AG in Kidney and Dialysis
- Vol. 2 (1) , 16-37
Open AccessAntisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease
Chronic kidney disease (CKD) is a global public health issue that places an increasing burden on the healthcare systems of both the developed and developing countries. CKD is a progressive and irreversible condition, affecting approximately 10% of the population worldwide. Patients that have progressed to end-stage renal disease (ESRD) require expensive renal replacement therapy, i.e., dialysis or kidney transplantation. Current CKD therapy largely relies on the use of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs). However, these treatments by no means halt the progression of CKD to ESRD. Therefore, the development of new therapies is urgently needed. Antisense oligonucleotide (ASO) has recently attracted considerable interest as a drug development platform. Thus far, eight ASO-based drugs have been granted approval by the US Food and Drug Administration for the treatment of various diseases. Herein, we review the ASOs developed for the identification of CKD-relevant genes and/or the simultaneous development of the ASOs as potential therapeutics towards treating CKD.